Use of the Systemic Immune-Inflammation Index to Predict Treatment Efficacy in Patients with Bladder Pain Syndrome

Basit Öğe Kaydı
dc.authoridSAHIN, MEHMET FATIH/0000-0002-0926-3005
dc.contributor.authorSahin, Mehmet Fatih
dc.contributor.authorEseoglu, Esad
dc.contributor.authorAkgul, Murat
dc.contributor.authorMalak, Arzu
dc.contributor.authorDogan, Cagri
dc.contributor.authorYazici, Cenk Murat
dc.date.accessioned2024-10-29T17:59:06Z
dc.date.available2024-10-29T17:59:06Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: To determine the relationship between bladder pain syndrome (BPS) and systemic inflammatory index (SII) and to examine the impact of treatment protocols on it. Study Design: Observational Study. Place and Duration of the Study: Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkiye, from January 2017 to December 2022. Methodology: A retrospective analysis was conducted on 30 BPS patients who underwent medical therapy. Upon diagnosis, the patients completed the king's health questionnaire (KHQ), beck depression questionnaire (BDQ), beck anxiety questionnaire (BAQ), and short form (SF -36) quality of life form. Peripheral blood SII was measured. After six months of regular therapy, the SII was recalculated when the patients completed the same forms again. The SII was compared between instances when patients reported more complaints, higher form scores, and instances when they reported fewer and lower scores. Results: The patients had a mean age of 46.1 +/- 13.6 years, with four males and 26 females. The mean follow-up duration was 76.3 +/- 24.5 months. Five patients of KHQ subcategories showed statistically significant decreases following therapy (52 to 39.17, 66.66 to 54.16, 54.40 to 41.07, 75.55 to 58.14, and 60.55 to 40.47). All patients of SF -36 components increased (p = 779, p = 0.393, p = 0.007, p = 0.004, p = 0.008, p = 0.041, p = 0.010, and p = 0.767, respectively). BDQ and BAQ decreased after therapy (11.55 to 11.41 and 11.86 to 11.24, respectively). Lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and SII decreased significantly (p = 0.001, 0.019, 0.002 and 0.039, respectively). Conclusion: SII, lymphocyte count, NLR, and PLR decreased after treatment, similar to BDQ and BAQ. SII is a simple and feasible method for evaluating the treatment efficacy of BPS.
dc.identifier.doi10.29271/jcpsp.2024.05.556
dc.identifier.endpage560
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue5en_US
dc.identifier.pmid38720216
dc.identifier.scopus2-s2.0-85192595687
dc.identifier.scopusqualityQ3
dc.identifier.startpage556
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2024.05.556
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14628
dc.identifier.volume34
dc.identifier.wosWOS:001245516800011
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherColl Physicians & Surgeons Pakistan
dc.relation.ispartofJcpsp-Journal of The College of Physicians and Surgeons Pakistan
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBladder pain syndrome
dc.subjectLymphocyte
dc.subjectNeutrophil
dc.subjectSystemic immune inflammation index
dc.subjectPlatelet
dc.titleUse of the Systemic Immune-Inflammation Index to Predict Treatment Efficacy in Patients with Bladder Pain Syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu